Related Experiment Video
Updated: Apr 17, 2026

Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier
Published on: November 12, 2013
Caveolin-1 mediates tissue plasminogen activator-induced MMP-9 up-regulation in cultured brain microvascular
Xinchun Jin1, Yanyun Sun, Ji Xu
1Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases and Institute of Neuroscience, The Second Affiliated Hospital of Soochow University, Soochow University, Suzhou, China.
Abstract:
Thrombolysis with tissue plasminogen activator (tPA) increases matrix metalloproteinase-9 (MMP-9) activity in the ischemic brain, which exacerbates blood-brain barrier injury and increases the risk of symptomatic cerebral hemorrhage. The mechanism through which tPA enhances MMP-9 activity is not well understood. Here we report an important role of caveolin-1 in mediating tPA-induced MMP-9 synthesis. Brain microvascular endothelial cell line bEnd3 cells were incubated with 5 or 20 μg/ml tPA for 24 hrs before analyzing MMP-9 levels in the conditioned media and cellular extracts by gelatin zymography. tPA at a dose of 20 μg/mL tPA, but not 5 μg/mL, significantly increased MMP-9 level in cultured media while decreasing it in cellular extracts. Concurrently, tPA treatment induced a 2.3-fold increase of caveolin-1 protein levels in endothelial cells. Interestingly, knockdown of Cav-1 with siRNA inhibited tPA-induced MMP-9 mRNA up-regulation and MMP-9 increase in the conditioned media, but did not affect MMP-9 decrease in cellular extracts. These results suggest that caveolin-1 critically contributes to tPA-mediated MMP-9 up-regulation, but may not facilitate MMP-9 secretion in endothelial cells. Thrombolysis with tissue plasminogen activator (tPA) increases matrix metalloproteinase-9 (MMP-9) activity in the ischemic brain, which exacerbates ischemic blood brain barrier (BBB) injury and increases the risk of symptomatic cerebral hemorrhage. Our results suggest a novel mechanism underlying this tPA-MMP 9 axis. In response to tPA treatment, caveolin-1 protein levels increased in endothelial cells, which mediate MMP-9 mRNA up-regulation and its secretion into extracellular space. Caveolin-1 may, however, not facilitate MMP-9 secretion in endothelial cells. Our data suggest caveolin-1 as a novel therapeutic target for protecting the BBB against ischemic damage. The schematic outlines tPA-induced MMP-9 upreguation.
Insights
Tissue plasminogen activator (tPA) increases matrix metalloproteinase-9 (MMP-9) via caveolin-1 in brain endothelial cells. This finding suggests caveolin-1 as a therapeutic target to protect the blood-brain barrier (BBB) during stroke treatment.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Thrombolysis with tissue plasminogen activator (tPA) is crucial for ischemic stroke treatment.
- tPA increases matrix metalloproteinase-9 (MMP-9) activity, exacerbating blood-brain barrier (BBB) injury and hemorrhage risk.
- The precise mechanism of tPA-induced MMP-9 elevation remains unclear.
Purpose of the Study:
- To investigate the role of caveolin-1 in mediating tPA-induced MMP-9 synthesis and activity.
- To elucidate the molecular mechanisms linking tPA, caveolin-1, and MMP-9 in endothelial cells.
Main Methods:
- Brain microvascular endothelial cells (bEnd3) were treated with varying doses of tPA.
- MMP-9 levels in conditioned media and cell extracts were analyzed using gelatin zymography.
- Caveolin-1 (Cav-1) protein and MMP-9 mRNA levels were assessed after tPA treatment and Cav-1 knockdown via siRNA.
Main Results:
- tPA (20 μg/mL) significantly increased extracellular MMP-9 while decreasing intracellular levels.
- tPA treatment elevated caveolin-1 protein levels by 2.3-fold in endothelial cells.
- Knockdown of Cav-1 inhibited tPA-induced MMP-9 mRNA up-regulation and extracellular secretion.
Conclusions:
- Caveolin-1 plays a critical role in mediating tPA-induced MMP-9 up-regulation in endothelial cells.
- Caveolin-1 appears to facilitate MMP-9 synthesis and extracellular release, but not necessarily secretion.
- Targeting caveolin-1 may offer a novel therapeutic strategy to protect the BBB during thrombolytic therapy for stroke.
More Related Videos
09:10Ex Vivo Imaging of Postnatal Cerebellar Granule Cell Migration Using Confocal Macroscopy
Published on: May 12, 2015
10:59Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
Related Concept Videos
Role of Matrix Metalloproteases in Degradation of ECM
Intracellular Signaling Affects Focal Adhesions
Some...
Regulation of Angiogenesis and Blood Supply